The logic behind the conventional approach is simple: because glioblastoma cells creep microscopically into surrounding tissue, the radiation field must be larger than the visible tumor. But histopathologic and preclinical studies have long shown that glioblastoma does not spread isotropically. Instead, it migrates preferentially along large white matter pathways, the bundled fiber tracts that connect distant brain regions. The tumor behaves less like an inflating balloon and more like water flowing through a network of pipes, racing along highways of myelinated axons while slowing at natural barriers. Yet this biological reality has never been systematically built into radiotherapy planning, until now.

A team led by Michael Wahl of the University of California, San Francisco, together with colleagues across UCSF’s radiation oncology, neurology, radiology and neurosurgery departments, has now translated that insight into a clinically workable technique. Their method uses diffusion-weighted MRI, which measures how freely water molecules diffuse through tissue. In organized white matter, water diffuses preferentially along the axis of the fiber bundles, a phenomenon called anisotropy. Tractography algorithms exploit this signal to reconstruct the trajectories of white matter fiber pathways throughout the entire brain, effectively drawing a wiring diagram of each individual patient.

The technical pipeline behind the study is a careful exercise in modern imaging science. Thirteen glioblastoma patients underwent 55-direction high angular resolution diffusion imaging on a 3 Tesla scanner as part of their postoperative radiation planning MRI, an acquisition of only seven to eight minutes. After correcting the data for head motion and eddy-current distortion using the FMRIB Software Library, the researchers fit both a tensor model and a higher-order Q-ball model with the open-source DIPY package, the latter to accurately resolve regions where fiber bundles cross. White matter, defined as voxels with fractional anisotropy above 0.15, was seeded densely, and a residual-bootstrap tractography approach estimated fiber orientations probabilistically, terminating streams when anisotropy fell below threshold or fibers bent more than sixty degrees.

Here is where the innovation crystallizes. The team selected all tractography streamlines passing within five millimeters of the visible tumor, the gross tumor volume delineated from the surgical cavity, contrast-enhancing regions and mass-like T2-FLAIR abnormality. From this subset they generated a scalar map in which every voxel stores its minimum white matter path length to the tumor, the shortest distance along actual fiber tracts rather than straight-line distance. The result is an anatomically informed expansion: the target flows along the superior cingulum bundle in one patient, crosses to the opposite hemisphere through the splenium of the corpus callosum in another, and in a third tracks along the inferior longitudinal fasciculus, precisely the routes along which those tumors later spread. In every one of the thirteen cases, the resulting contours respected natural anatomic boundaries that the standard circular expansion ignored.

The payoff appears in the numbers. When the researchers generated clinical target volumes by thresholding the path length maps at two centimeters and compared them, within the same patient, to the guideline-conformant two-centimeter isotropic expansion, the tractography-based volumes were a median of 67 cubic centimeters smaller, roughly a nineteen percent reduction, a difference that reached statistical significance. The one-centimeter variant shrank targets even more dramatically, by 39 percent on average, though at the cost of missing several recurrences captured by the standard volume. At three centimeters, the tractography volume converged with the standard one, as expected. These volumes were imported directly into the RayStation treatment planning system, demonstrating that the approach is compatible with routine clinical workflows rather than confined to research software.

The more consequential question is whether these sculpted volumes actually contain the places where tumors come back. To answer it, the team performed a patterns-of-failure analysis, rigidly registering each patient’s recurrence MRI to the planning scans and classifying recurrences as central, in-field, marginal or distant relative to each target definition. The median time to recurrence was twelve months. Ten of the thirteen recurrence volumes fell entirely within the conventional isotropic target, but twelve of thirteen were encompassed by the two-centimeter tractography-based volume, all while that volume was substantially smaller. In two cases, the recurrent tumor was clearly infiltrating along a major white matter tract inside the tractography target but outside the standard one, exactly the failure mode the technique was designed to prevent.

The clinical context makes these findings timely. Historical teaching held that ninety percent of glioblastoma recurrences occur within a two-centimeter margin of the original tumor, a figure that discouraged tinkering with target delineation. But more recent studies of patients treated with concurrent temozolomide, particularly those whose tumors carry methylation of the MGMT promoter and are therefore more drug-sensitive, have shown marginal or distant recurrence rates approaching forty percent, suggesting that current volumes may undertreat pockets of microscopic disease in some patients. At the same time, generous circular expansions irradiate substantial volumes of healthy brain, raising the specter of radiation necrosis and long-term neurocognitive decline. An approach that could simultaneously tighten targets and extend them along true routes of invasion promises the rarest of things in oncology: better coverage with less collateral damage.

The researchers are appropriately measured about what their study can and cannot claim. Thirteen patients cannot prove a statistical reduction in marginal or distant recurrences, and the pattern-of-failure analysis was observational and hypothesis-generating. Even demonstrating that a recurrence fell within a tractography target does not prove that treating that volume would have prevented it, since most patients still recur within the high-dose region regardless of technique. The small sample also prevented confident optimization of the tracking parameters and path length thresholds, and no dosimetric analysis of organ-at-risk sparing has yet been performed. Validation in a larger prospective cohort, with formal assessment of normal brain sparing through dose-volume statistics, is the clearly stated next step.

Still, as a proof of concept, the study is striking in its feasibility and simplicity. The imaging sequence adds only minutes to a standard planning MRI, the analysis relies on open-source tools, and the output drops directly into commercial treatment planning software. What the UCSF team has shown is that the brain’s own anatomy can be enlisted as a map of where an incurable tumor is likely to travel next, replacing a geometric convention inherited from decades-old CT studies with a personalized, biologically grounded contour. If larger trials confirm that two centimeters along a nerve fiber tract is worth more than two centimeters in a straight line, the humble circle that has defined glioblastoma radiotherapy for a generation may finally be retired, and one of medicine’s grimmest diagnoses may gain a small but meaningful edge.

Subject of Research: Tractography-based clinical target volume delineation for glioblastoma radiotherapy planning

Article Title: White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma

Article References: Wahl, M., Chapman, C. H., Morin, O., Jordan, K., Henry, R. G., Chang, S. M., Villanueva-Meyer, J. E., Mukherjee, P., Theodosopoulos, P., McDermott, M. W., Berger, M. S., Sneed, P., Braunstein, S. E., & Lupo, J. M. (2026). White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma. Journal of Neuro-Oncology, 179(3), Article 102. https://doi.org/10.1007/s11060-026-05789-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05789-9

Keywords: glioblastoma, diffusion-weighted MRI, tractography, radiotherapy planning, white matter, clinical target volume, patterns of failure, tumor recurrence, neuro-oncology, UCSF, temozolomide, medical imaging

The technique rests on diffusion-weighted MRI, which sensitizes the MR signal to the random Brownian motion of water molecules. In a typical acquisition, the signal is measured along many diffusion-encoding directions, and a model is fitted to describe how the apparent diffusion coefficient varies with direction. In most brain tissue, diffusion is restricted and anisotropic, meaning water moves more easily along axonal bundles than across them. Free water imaging extends the standard diffusion tensor model by adding an isotropic compartment: a fraction of the voxel’s water is assumed to diffuse freely and equally in all directions, unconstrained by tissue microstructure. The estimated volume fraction of this compartment, often called the free water fraction, is the quantity that studies have linked to Parkinson’s disease.

What the commentary emphasizes is that this seemingly single number is, in practice, the product of a long chain of decisions. Every stage of the pipeline matters: the strength and number of diffusion-encoding gradients, the number of directions acquired, the echo time and voxel size, the correction for head motion and eddy currents, the approach to removing non-brain tissue, the handling of signal dropout, the fitting algorithm used to estimate the free water fraction, and the way regions of interest are defined in the midbrain. Each of these choices can shift the estimated values, and because different studies make different choices, their results are not always directly comparable.

This matters acutely in Parkinson’s disease research because the effect sizes involved are modest. The changes in free water fraction reported between people with Parkinson’s disease and healthy controls are typically small in absolute terms, often on the order of a few tenths of a percent to a few percent of the signal fraction. When the biological signal is that subtle, even small methodological differences can rival or exceed the effect being sought. A pipeline that smooths data aggressively, or that defines the substantia nigra generously, may report group differences where a more conservative pipeline finds none. Conversely, an underpowered or noisy acquisition may obscure real biology. The commentary’s central claim is that free water imaging findings in Parkinson’s disease should therefore be read as conditional statements, valid for a particular acquisition, preprocessing stream, and region-of-interest strategy, rather than as universal truths about the diseased brain.

The stakes are high because free water imaging has been proposed as a candidate imaging biomarker for disease progression and for use in clinical trials. Several longitudinal studies have suggested that free water fraction in the substantia nigra increases over time in people with Parkinson’s disease, raising hopes that the measure could serve as a sensitive endpoint for disease-modifying therapies. If those hopes are to be realized, the field needs to know how much of the measured change reflects biology and how much reflects the measurement apparatus. A biomarker that drifts with scanner software updates, or that responds more strongly to a change in preprocessing than to a change in the disease, cannot support the weight of a multi-center trial.

The commentary also addresses a conceptual trap: the tendency to interpret an elevated free water fraction as a direct, one-to-one readout of neuroinflammation. The biological rationale is plausible, because inflammatory processes such as astrocytic activation and microglial responses can expand the extracellular space and increase the mobility of water. But elevated free water is not specific to inflammation. Edema, enlarged perivascular spaces, tissue atrophy with partial volume effects from cerebrospinal fluid, and even residual artifacts from motion or susceptibility gradients can all inflate the estimate. Treating free water fraction as a binary indicator of an active inflammatory process, present or absent, oversimplifies what is in fact a composite measurement influenced by multiple tissue properties and multiple sources of error.

Partial volume contamination deserves particular attention in the midbrain, where the structures of interest are small and intimately surrounded by cerebrospinal fluid spaces. The substantia nigra lies adjacent to the interpeduncular cistern, and even with careful region-of-interest placement, signal from free cerebrospinal fluid can leak into the measured voxels, especially at the resolutions commonly used in research scanning. Some pipelines attempt to correct for this, while others rely on conservative masking. The commentary suggests that differences in how this problem is handled may explain a substantial portion of the variability in the literature, with some studies reporting robust group differences and others reporting null results for ostensibly similar comparisons.

None of this, the authors are careful to note, amounts to a dismissal of free water imaging. On the contrary, the technique remains one of the most promising MRI-based approaches to the nigral pathology that defines Parkinson’s disease, precisely because it targets a biologically meaningful property of tissue rather than a gross structural change that appears only late in the disease course. The argument is for methodological transparency and rigor: studies should report their acquisition parameters and preprocessing steps in full, share their analysis code where possible, and validate their pipelines against phantom data or across independent datasets. Harmonization efforts across scanning sites, and sensitivity analyses that show how results change under alternative processing choices, would allow the field to distinguish findings that are robust from those that are artifacts of a particular workflow.

For clinicians and trial designers, the practical message is one of calibrated expectations. Free water imaging is not yet a diagnostic test, and a single elevated value in an individual patient should not be read as a verdict on their disease state. The technique’s near-term value lies in group-level comparisons and longitudinal tracking within carefully controlled studies, where its sensitivity to change can be exploited while its methodological dependencies are held constant. As the field moves toward standardization, the commentary argues, the goal should be pipelines whose outputs are stable across sites and scanners, so that the biological signal of neurodegeneration can finally be separated from the technical noise of measurement. In free water imaging, the method is not a mere technicality; it is part of the result itself, and recognizing that is the first step toward turning an intriguing research measurement into a dependable clinical tool.

Subject of Research: The influence of image processing methodology on free water imaging measurements in Parkinson's disease

Article Title: The method matters: free water imaging in Parkinson’s disease is not a binary verdict

Article References: The method matters: free water imaging in Parkinson’s disease is not a binary verdict. (n.d.). https://doi.org/10.1038/s41531-026-01492-8

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01492-8

Keywords: Parkinson's disease, free water imaging, diffusion MRI, neuroinflammation, biomarkers, image processing, substantia nigra, magnetic resonance imaging, neurodegeneration, methodology, method, matters